These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 24379206)

  • 1. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.
    Drawz SM; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2014; 58(4):1835-46. PubMed ID: 24379206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
    Liscio JL; Mahoney MV; Hirsch EB
    Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
    Falcone M; Paterson D
    J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.
    Nicolau DP
    Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
    Zhanel GG; Lawson CD; Adam H; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Denisuik A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2013 Feb; 73(2):159-77. PubMed ID: 23371303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
    Durand-Réville TF; Guler S; Comita-Prevoir J; Chen B; Bifulco N; Huynh H; Lahiri S; Shapiro AB; McLeod SM; Carter NM; Moussa SH; Velez-Vega C; Olivier NB; McLaughlin R; Gao N; Thresher J; Palmer T; Andrews B; Giacobbe RA; Newman JV; Ehmann DE; de Jonge B; O'Donnell J; Mueller JP; Tommasi RA; Miller AA
    Nat Microbiol; 2017 Jun; 2():17104. PubMed ID: 28665414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor.
    Reck F; Bermingham A; Blais J; Casarez A; Colvin R; Dean CR; Furegati M; Gamboa L; Growcott E; Li C; Lopez S; Metzger L; Nocito S; Ossola F; Phizackerley K; Rasper D; Shaul J; Shen X; Simmons RL; Tang D; Tashiro K; Yue Q
    ACS Infect Dis; 2019 Jul; 5(7):1045-1051. PubMed ID: 30861342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New β-Lactamase Inhibitors in the Clinic.
    Papp-Wallace KM; Bonomo RA
    Infect Dis Clin North Am; 2016 Jun; 30(2):441-464. PubMed ID: 27208767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012.
    Sader HS; Castanheira M; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2014; 58(3):1684-92. PubMed ID: 24379201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Delhi metallo-β-lactamase (NDM-1): an update.
    Shakil S; Azhar EI; Tabrez S; Kamal MA; Jabir NR; Abuzenadah AM; Damanhouri GA; Alam Q
    J Chemother; 2011 Oct; 23(5):263-5. PubMed ID: 22005056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.
    Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Quale J; Landman D
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4856-60. PubMed ID: 26033723
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interplay between β-lactamases and new β-lactamase inhibitors.
    Bush K; Bradford PA
    Nat Rev Microbiol; 2019 May; 17(5):295-306. PubMed ID: 30837684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.